FDA issues alert on potential dangers of unproven treatment for multiple sclerosis
date:May 11, 2012
is procedure is effective in treating MS, FDA encourages rigorously-conducted, properly-targeted research to evaluate the relationship between CCSVI and MS, said William Maisel, M.D., M.P.H., chief scientist and deputy director for science in the FDAs Center for Devices and Radiological Health. Patients are encouraged to discuss the potential risks and benefits of this procedure with a neurologist or other physician who is familiar with MS and CCSVI, including the CCSVI procedures and their outc
2/6 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/02 23:55